Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine

Sanofi Pasteur, the vaccines division of Sanofi SNY, announced today the results of a new study evaluating the immunogenicity and safety of an investigational quadrivalent inactivated influenza vaccine among adults 65 years of age and older. Currently licensed influenza vaccines target only three influenza virus strains anticipated to circulate in a given year. The data were presented at the 49th Annual Meeting of the Infectious Diseases Society of America on October 21, 2011. This study affirms the findings of a previous study on QIV presented last year at IDSA in adults 18 years of age and older. The results of the Phase II study indicated that the addition of an alternate-lineage B strain does not adversely affect the safety or immunogenicity profile of QIV compared to the currently licensed trivalent inactivated vaccine, Fluzone® (Influenza Virus Vaccine). In addition to the data in elderly adults presented today, a Phase III study in children 6 months through 18 years of age also is underway with data anticipated later this year.